CVM•benzinga•
Reported Earlier, CEL-SCI Prices $5M Public Offering At $2.50/Share To Advance Multikine Cancer Immunotherapy Development
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 22, 2025 by benzinga